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Abstract
Recent studies have revealed that TAK1 kinase is an essential intermediate in several innate
immune signaling pathways. In this study, we investigated the role of TAK1 signaling in
maintaining intestinal homeostasis by generating enterocytes-specific constitutive and inducible
gene deleted TAK1 mice. We found that enterocyte-specific constitutive TAK1 deleted mice
spontaneously developed intestinal inflammation as observed by histological analysis and
enhanced expression of IL-1β, MIP2 and IL-6 around the time of birth, which was accompanied
by significant enterocytes apoptosis. When TAK1 was deleted in the intestinal epithelium of 4-
week-old mice using an inducible knockout system, enterocytes underwent apoptosis and
intestinal inflammation developed within 2–3 days following the initiation of gene deletion. We
found that enterocytes apoptosis and intestinal inflammation were strongly attenuated when
enterocyte-specific constitutive TAK1 deleted mice were crossed to TNF receptor 1 (TNFR1)−/−
mice. However, these mice later (>14 days) developed ileitis and colitis. Thus, TAK1 signaling in
enterocytes is essential for preventing TNF-dependent epithelium apoptosis and the TNF-
independent development of ileitis and colitis. We propose that aberration in TAK1 signaling
might disrupt intestinal homeostasis and favor the development of inflammatory disease.
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Intestinal epithelium acts as a barrier against commensal and pathogenic bacteria by
physically preventing their invasion as well as by activating the innate immune system to
control bacterial colonization (1–4). Commensal bacteria constantly stimulate enterocytes
through Toll-like receptors and intracellular bacterial sensors such as NODs. This
stimulation is believed to be important in maintaining the physical barrier and to promote
expression of cytokines/chemokines under steady-state conditions. Dysregulation of the
innate immunity and loss of the intestinal physical barrier cause bacterial invasion and
excessive production of cytokines/chemokines, which are associated with chronic
inflammatory diseases such as inflammatory bowel disease (IBD) (5,6).
Transforming growth factor β-activated kinase 1 (TAK1) is an essential intermediate of
innate immune signaling pathways. TAK1 is activated by Toll-like receptor ligands, as well
as by inflammatory cytokines such as TNF and IL-1 (7–9). Furthermore, we have recently
identified that TAK1 is also activated by the intracellular bacterial sensor NOD2 in skin
epithelial cells (10). Following activation, TAK1 stimulates signaling pathways leading to
the activation of two groups of transcription factors, AP-1 and NF-κB, which results in
increased production of cytokines/chemokines. Therefore, it might be expected that TAK1
would play an important role in maintaining epithelial barrier function by this regulation of
cytokines/chemokine production. In addition, it has been demonstrated that TAK1
deficiency results in an increased sensitivity to TNF-mediated apoptosis in fibroblasts and
keratinocytes (8,9,11), which could be involved in tissue damage as discussed below.
Among inflammatory cytokines, TNF has a unique ability to induce cell death and tissue
damage (12,13). TNF activates two opposing intracellular signaling pathway; one which
activates anti-apoptotic pathways through the transcription factors NF-κB and AP-1; and
another which induces caspase-dependent apoptosis through Fas-associated death domain
(FADD) and pro-caspase 8 (also called FLICE) (12,14). TNF can presumably cause tissue
damage when this pro-apoptotic pathway is predominantly activated. Indeed, TNF is closely
associated with tissue damage in chronic inflammatory diseases, and anti-TNF therapy has
been proven to be effective to reduce tissue damage (15). However, in most types of cells,
TNF does not induce apoptosis because the anti-apoptotic pathway overrides the pro-
apoptotic pathway (14). In the normal intestinal epithelium, TNF, even at very high
concentration, cannot cause any damage (16). Thus, the mechanism by which TNF promotes
tissue damage in chronic inflammatory diseases has not fully been elucidated.
We speculate that TAK1 may regulate intestinal epithelial integrity by controlling innate
immunity in enterocytes and by modulating TNF-induced apoptosis and tissue damage. In
this study, we examined the role of TAK1 in the intestinal epithelium by generating and
characterizing mice with an intestinal enterocyte-specific deletion of TAK1. We found that
deletion of TAK1 causes TNF-dependent tissue damage. We also found that enterocyte-




Mice carrying a floxed Map3k7 allele (TAK1FL/FL) (17) with a C57BL/6/129 mixed
background were used for generating villin-CreTAK1FL/FL and villin-CreTAK1FL/FL
TNFR1−/− mice. We also generated villin-CreTAK1FL/FL and villin-CreTAK1FL/FL
TNFR1−/− mice using TAK1FL/FL that were backcrossed to C57BL/6 for at least 5
generations, and we confirmed that the same phenotypes were observed using the
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backcrossed TAK1FL/FL mice. The backcrossed TAK1FL/FL mice were use to generate villin-
CreERT2TAK1FL/FL mice. Mice carrying a villin-Cre with a C57BL/6 background (18) were
from Jackson Lab, villin-CreERT2 with a C57BL/6 background were described previously
(19), and TNFR1-deficient mice C57BL/6 Tnfrsf1atm1Mak (TNFR1−/−) (20) were from
Jackson Laboratory. In all experiments, littermates were used as controls. To induce
recombination, 4-week-old mice were given intraperitoneal injections of tamoxifen (1 mg
per 20 g body weight) for 2 to 3 consecutive days. Mice were bred and maintained under
specific pathogen-free conditions. All animal experiments were done with the approval of
the North Carolina State University Institutional Animal Care and Use Committee.
Histology
Sections from the small intestine (jejunum and ileum) and the colon (proximal and distal)
were stained with hematoxylin and eosin for histological analysis. Mucosal inflammation
was evaluated in cross-sections of the small intestine and the colon separately. Sections were
scored in a blinded fashion on a scale from 0 to 4, based on the degree of lamina propria
mononuclear cell infiltration, crypt hyperplasia, goblet cell depletion and architectural
distortion, as previously described (21). To detect apoptotic cells, TUNEL assay was
performed on paraffin sections using the DeadEnd™ Colorimetric TUNEL System
(Promega) according to the manufacturer's instructions. Immunofluorescence was performed
on frozen sections using polyclonal antibody against cleaved caspase 3 (1:200, Cell
Signaling), TAK1 (1:200) (Ninomiya-Tsuji 1999), lysozyme (1:200, Novocastra), Ki67
(1:500, Novocastra), synaptophysin (1:100, Thermo Scientific), and monoclonal antibody
against Nidogen (1:1000, Chemicon). Bound antibodies were visualized by Cy2- or Cy3-
conjugated secondary antibodies against rabbit (1:500, GE healthcare) or rat (1:100,
Chemicon). Nuclei were counterstained with DAPI. For the detection of intestinal goblet
cells, paraffin-embedded sections were stained with Alcian Blue and with Nuclear Fast Red
as counterstain.
Isolation of enterocytes
Enterocytes were isolated as described previously (22,23). Briefly, the whole small intestine
was harvested and flushed with PBS to remove fecal contents. One end of the intestine was
tied off, filled with Hanks’ Balanced Salt Solution (HBSS, Sigma-Aldrich) containing 10
mM EDTA and incubated in a PBS bath at 37°C for 5 min. After removing the contents, the
intestine was filled with PBS containing 1.5 mM EDTA and 0.5 mM DTT and incubated in
PBS again for 10 min. The contents were collected into tubes and centrifuged at 1,200 rpm
for 5 min. The resulting pellets containing predominantly epithelial cells were washed twice
in cold PBS.
Immunoblot analysis
Enterocytes isolated from the small intestine were lysed in an extraction buffer (20 mM
HEPES, pH 7.4, 150 mM NaCl, 12.5 mM β-glycerophosphate, 1.5 mM MgCl2, 2 mM
EGTA, 10 mM NaF, 2 mM dithiothreitol, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 100 units/ml aprotinin, 0.5% Triton X-100). Proteins from cell lysates were
electrophoresed by SDS-PAGE and transferred to Hybond-P (GE Healthcare). The
membranes were immunoblotted with a polyclonal antibody against TAK1 described
previously (7) and a monoclonal antibody against β-actin (Sigma). Bound antibodies were
visualized with horseradish peroxidase-conjugated antibodies against rabbit or mouse IgG
using the ECL Western blotting system (GE).
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Isolated enterocytes and liver, kidney and heart were roughly disrupted in lysis buffer (50
mM Tris-HCl, pH 7.4, 100 mM EDTA, pH 8.0, 100 mM NaCl, 1% SDS). The following
primers were used: floxed TAK1, GGCTTTCATTGTGGAGGTAAGCTGAGA and
GGAACCCGTGGATAAGTGCACTTGAAT; villin-Cre,
GTGTGGGACAGAGAACAAACC and ACATCTTCAGGTTCTGCGGG; villin-CreERT2,




Total RNA from the ileum and middle of the colon were isolated using RNeasy Mini
(Qiagen). cDNA was synthesized using TaqMan reverse transcription reagents (Applied
Biosystems). mRNA levels of a non-truncated (full length) form of TAK1 were analyzed by
real-time PCR with SYBR Green (Applied Biosystems). Full-length TAK1 primers,
CGTCTTCTGCCAGTGAGATG (in the exon1) and ATCTTTTGCTCTCCACTTAGCTT
(in the exon 2 flanked by loxP); glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
primer, GAAGGTCGCTGTGAACGGA and GTTAGTGGGGTCTCGCTCCT were used.
Expression levels of IL-1β, IL-6, MIP2, S100A9 and TNF were also analyzed by TaqMan
gene expression assay (Applied Biosystems). Results were analyzed using the comparative
Ct Method. All values were normalized to the level of GAPDH messenger RNA.
ELISA
Frozen jejunum were ground into powder in liquid nitrogen, homogenized in cold-PBS
containing a protease inhibitor cocktail (Calbiochem) and centrifuged at 14,000rpm, 4 °C for
5 min. Protein concentrations were determined by BCA Protein Assay Reagent Kit
(PIERCE). IL-6 and IL-1β levels were analyzed using commercially available mouse IL-6
and IL-1b kits, respectively (BD Bioscience). ELISA was performed following
manufacture’s instruction. IL-6 and IL-1β levels were standardized to the total protein
amount and data presented as ng of cytokine per mg of total protein.
Statistical analysis
Statistical comparisons were made using paired or independent, two-tailed Student's t-tests
assuming equal variance and two-tailed Welch's t-tests assuming unequal variance.
Results
Intestinal epithelium-specific deletion of TAK1 causes intestinal damage
TAK1 is ubiquitously expressed in the intestinal tissues including intestinal epithelium,
lamina propria, and smooth muscle, at least from embryonic day 16.5 (E16.5) to the adult
stage (Fig. 1a and data not shown). To investigate TAK1 function in the intestinal
epithelium, we generated mice lacking functional TAK1 specifically in enterocytes. Mice
carrying loxP-flanked TAK1 allele (TAK1FL) (17) were crossed with villin-Cre transgenic
mice (18) to generate villin-CreTAK1FL/FL mice. In this floxed TAK1 system, Cre
recombinase catalyzes the deletion of the TAK1 ATP binding site, amino acids 41–77,
resulting in the generation of a truncated/kinase-dead form of TAK1 (TAK1Δ) (11,17). In
villin-CreTAK1FL/FL mice, we anticipate that a truncated/kinase-dead version of TAK1
(TAK1Δ) is expressed in enterocytes, while a wild-type TAK1 is expressed in other cell
types. We note that earlier studies have revealed that TAK1 deletion mice in that entire
TAK1 expression is abolished (24–26) exhibit the same phenotypes as this TAK1 deletion
(TAK1Δ/Δ) mice in embryos and T cells, (8,17). Since neonatal villin-CreTAK1FL/FL mice
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died as described below, we were not able to isolate enterocytes. To determine whether
TAK1 is deleted in enterocytes, we performed several experiments using villin-
CreERT2TAK1FL/FL (inducible KO) and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice,
which will be described later.
villin-CreTAK1FL/FL mice were born at the expected Mendelian ratio, however they showed
severe intestinal bleeding within 1 day of birth and died by P1. The small intestine and the
colon from villin-CreTAK1FL/FL mice showed hemorrhage at P0, while the intestine was
grossly normal at E18.5 (Fig. 1b). The lengths of the small intestine and the colon were
shorter in villin-CreTAK1FL/FL mice at P0 than in control TAK1FL/FL mice (Fig. 1c), while
the colon length at E18.5 was not significantly different (data not shown). The control
TAK1FL/FL mice, as well as mice with intestinal epithelium-specific heterozygous deletion
of TAK1 (villin-CreTAK1FL/+), did not show any gross abnormalities (data not shown). The
small intestine and colon of villin-CreTAK1FL/FL mice at E15.5 and E17.5 were
indistinguishable from control mice (data not shown). Histological analysis revealed that the
small intestine and the colon showed evidence of inflammation at both E18.5 and P0 with
architecturally disrupted epithelium and enhanced immune cell infiltration (Fig. 1d and e).
We found that villi and crypts are formed normally in villin-CreTAK1FL/FL mice by E18.5
(Fig. 1e) with no difference in crypts-villi length between control and mutant mice at E18.5
(Fig. 1f).
Therefore, we assume that intestinal development is not altered by deletion of TAK1. To
further examine intestinal epithelium differentiation, we stained goblet cells and
enteroendocrine cells. We also examined the level of metalloproteinase 7 (paneth cell
marker) and neurogenin 3 (enteroendocrine cell marker). The numbers of goblet cells (Fig.
1g) and enteroendocrine cells (Fig. 1h) and the expression levels of metalloproteinase 7 and
neurogenin 3 (Fig. 1i) were not markedly altered by TAK1 deletion. These data suggest that
TAK1 is largely dispensable for cell fate decision during differentiation. Therefore, TAK1-
deletion-induced intestinal epithelial damage is not due to a defect in development or
differentiation. We note that the size of the goblet cells was found to be smaller in villin-
CreTAK1FL/FL mice than those in the control animals (Fig. 1g). Because it is known that
goblet cell maturation is disrupted by inflammation, this may be a consequence of
inflammatory conditions rather than a direct effect of TAK1 deletion.
Mice with intestinal epithelium-specific deletion of TAK1 show increased apoptotic cell
number and inflammation
We speculated that the intestinal structural damage observed in villin-CreTAK1FL/FL mice
might be associated with cell death leading to inflammation. To verify these possibilities, we
examined apoptosis by TUNEL assay as well as staining of cleaved caspase 3, and
quantitated expression of inflammatory genes. The numbers of apoptotic cells markedly
increased in all sections of the small intestine and the colon from villin-CreTAK1FL/FL mice
at P0 compared to TAK1FL/FL mice (Fig. 2a and b). The pro-inflammatory chemokine MIP2
and chemotactic factor S100A9 were markedly up-regulated in the villin-CreTAK1FL/FL
small intestine and colon at P0 (Fig. 2c). At E18.5, we observed significant variability
among individual mice, with some villin-CreTAK1FL/FL mice exhibiting a striking increase
in apoptotic cell number (Fig. 2a and b). Increased apoptosis correlated with the
upregulation of proinflammatory cytokines and chemokines/chemotactic factors (Table 1).
No apoptotic cells were detected at E16.5 and E17.5 (data not shown). These results
demonstrate that apoptosis and inflammation are concomitantly induced around E18 in mice
harboring an intestinal epithelium-specific deletion of TAK1.
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TAK1 is required for prevention of apoptosis and inflammation in 4-week-old mice
Because of the severe intestinal damage observed at P0 in villin-CreTAK1FL/FL mice, we
next utilized an inducible Cre-mediated recombination system to fully assess the role of
TAK1 in adult mice. Mutant mice were generated by crossing TAK1FL/FL mice with villin-
CreERT2 transgenic mice expressing a tamoxifen-dependent recombinase (CreERT2) under
the control of the intestinal epithelium-specific villin promoter (19). In this system, a mutant
version of TAK1 (TAK1Δ) is generated in villin-expressing cells when mice are treated with
tamoxifen. In the absence of tamoxifen, villin-CreERT2TAK1FL/FL mice did not develop any
spontaneous phenotype at least by the age of 8 months. We treated villin-
CreERT2TAK1FL/FL mice with tamoxifen at the age of 4 weeks and observed that TAK1 was
effectively deleted (Fig. 3a–c).
Interestingly, villin-CreERT2TAK1FL/FL mice developed pathological conditions associated
with movement disorder, weight loss, and a mild diarrhea at only 3 days of consecutive
injection of tamoxifen. At day 2, villin-CreERT2TAK1FL/FL mice were grossly normal and
did not lose weight. However, histological analysis of villin-CreERT2TAK1FL/FL mice
showed that the structure of the small intestine was disrupted at day 2 (Fig. 3d), and
completely absent by day 3 (Fig. 3d). The colon structure of villin-CreERT2TAK1FL/FL mice
was relatively normal compared to the small intestine at day 2–3 (Fig. 3d). To examine
whether apoptosis and inflammation were associated with this intestinal damage, we
measured apoptosis by TUNEL assay and caspase 3 processing, and measured
proinflammatory cytokines/chemokines/chemotactic mRNA levels. At day 2, apoptotic cells
were markedly increased in the small intestine of the inducible TAK1 mutant mice,
especially in the crypts (Fig. 3e and f). Apoptotic cells were more scattered in the small
intestine at day 3, because most of epithelial cells had already been removed (Fig. 3e and f).
In the colon, the number of apoptotic cells was higher at day 3 compared to at day 2, and
apoptotic cells were observed mostly in the crypts. The levels of proinflammatory cytokines/
chemokines/chemotactic factors were up-regulated in the small intestine at day 2–3 (Fig. 3g
and data not shown). The inflammatory gene expression was increased in the colon of
inducible TAK1 mutant mice at day 2–3 (Fig. 3g). In addition, CD4+ T lymphocytes,
macrophages and dendritic cells were detected in the small intestine of TAK1 deleted mice
at day 3 (data not shown). These results demonstrate that TAK1 is essential for preventing
enterocyte death and development of intestinal inflammation not only in neonatal but also in
4-week-old mice.
The severity of intestinal damage and inflammation in the 4-week-old inducible TAK1
mutant mice after only 3 days of tamoxifen administration (Fig. 3d) was greater than that
observed in the E18.5 non-inducible TAK1 mutant mice (Fig. 1e). Because genetic
recombination was initiated at E12.5 in the embryonic midgut and highgut of non-inducible
villin-Cre mice (18), we had expected that deletion of the TAK1 allele would have been
efficiently induced before E18.5 in villin-CreTAK1FL/FL mice. However, we could not detect
pronounced increase in apoptosis by E18.5-P0 in the TAK1 mutant mice. We speculated that
4-week-old mice might express higher levels of some apoptotic inducer(s) than the neonatal
mice. We examined the level of one of best-known apoptotic inducers, TNF, in the
embryonic, neonatal and 4-week-old intestine by real-time PCR. We note that TNF
expression was not altered by genotype. Unlike other proinflammatory cytokines such as
IL-1 and IL-6, TNF was not greatly up-regulated by TAK1 deletion (data not shown).
However, we found that TNF expression was greatly increased in all genotype mice as mice
grew (Fig. 4). The levels of TNF seem to be correlated with the severity of intestinal damage
in the TAK1 mutant mice. Therefore, we assume that TNF may cause intestinal cell death
and inflammation in mice lacking TAK1 expression in the intestinal epithelium.
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Apoptosis and inflammatory defects caused by TAK1 deletion are rescued by inhibition of
TNF signaling
To verify the hypothesis that the phenotype observed in TAK1-deficient mice is due to
TNF-induced cell death, we generated double-mutant mice harboring a deletion of the
TNFR1 and containing villin-CreTAK1FL/FL (villin-CreTAK1FL/FL TNFR1−/−). Deletion of
the TAK1 gene in the double-mutant mice was confirmed by immunoblot in isolated
enterocytes and mRNA analysis in the whole intestine (Fig. 5a and b). We found that the
intestinal damage observed in villin-CreTAK1FL/FL neonatal mice was completely rescued
by deletion of TNFR1 (Fig. 5c). Few or no apoptotic cells were detected in the double-
mutant intestine (Fig. 5d) and the levels of cytokines/chemokines/chemotactic factors were
similar in the double-mutant intestine compared to those in the control TAK1FL/FL
TNFR1−/− mice (Fig. 5e). Goblet cells were also normal in the double mutant mice (Fig. 5f).
These results indicate that TNF is a major cause of apoptosis and inflammation induced in
the intestine harboring an epithelium-specific deletion of TAK1.
Double-mutant mice harboring intestinal epithelium-specific TAK1 deletion and TNFR1
deletion spontaneously develop ileitis and colitis
While abnormalities detected in villin-CreTAK1FL/FL neonatal mice were completely
rescued by deletion of TNFR1 deletion, we noticed that weight gain was reduced in villin-
CreTAK1FL/FL TNFR1−/− mice compared to control TAK1FL/FL TNFR1−/− mice at around
the age of 2–3 weeks (Fig. 6a). Histological analysis in the double-mutant mice that had lost
weight revealed that they developed ileitis and severe colitis (Fig. 6c). These double-mutant
mice showed shorter colon length (Fig. 6b), an enlargement of crypt cellularity in the small
intestine (Fig. 6d), and decrease of mature goblet cells (Fig. 6h). We found that apoptotic
cells were more numerous in the double-mutant mice (Fig. 6e and f) and proinflammatory
cytokines/chemokines/chemotactic factors were up-regulated (Fig. 6g). Despite the
enlargement of crypt cellularity, the number and distribution of paneth cells were found to
be normal in the double-mutant mice (Fig. 6i). This suggests that TAK1 deletion does not
alter the differentiation of intestinal cells but causes hyperplasia in the intestine. We detected
increased cellular proliferation in all regions of the small intestine and colon of the double-
mutant mice (Fig. 6j). This hyperplasia could be due to compensatory cell proliferation
induced by apoptosis and results of the proinflammatory milieu in these double mutant mice.
These results suggest that, even in the absence of TNF signaling, TAK is important for
preventing dysregulation in the intestinal epithelium, and its ablation causes ileitis and
colitis.
Discussion
It has been established that NF-κB is an important mediator of cell survival (14,27).
Abrogation of the NF-κB pathway by knockout of IKKβ or NEMO (IKKγ) causes
hypersensitivity to TNF-killing (28–30). In skin epidermis, deletion of NEMO causes TNF-
dependent cell death and thereby induces an inflammatory skin condition (31). This
pathology is very similar to that seen in mice having a skin epidermal-specific deletion of
TAK1 (11). TAK1 is an essential kinase in several intracellular signaling pathways and
functions upstream of IKK-NF-κB (7–9). This similarity in phenotypes between TAK1-
mutant and NEMO-mutant mice clearly indicates that TAK1-IKK-NF-κB is a major
pathway that prevents TNF-induced killing in the skin epidermis. In contrast, mice with
NEMO deletion in the intestinal epithelium have a phenotype that is somewhat different
from mice having an intestinal epithelium-specific deletion of TAK1, even though NEMO
and TAK1 were deleted by using the same Villin-Cre transgenic mice. Intestinal epithelium
with a NEMO deletion slowly developed abnormalities including colitis in the colon by the
age of 6 weeks (23). Cell death is detected in only a few scattered areas (23). In contrast, as
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shown in this report, deletion of TAK1 in the intestinal epithelium almost immediately
results in the death of enterocytes in the presence of TNF. This suggests that, although NF-
κB is partly involved in the survival of enterocytes, TAK1 is more critical to determining
their death or survival. Because TAK1 can activate not only NF-κB but also AP-1, AP-1
could be critically involved in enterocyte survival.
TAK1 deletion in the intestinal epithelium causes apoptosis and inflammation before birth,
suggesting that the intestinal microbiota is not involved in this inflammatory condition.
Because enterocyte apoptosis and intestinal inflammation was prevented in TNFR1 deleted
mice, we concluded that TNF expressed in the intestine is the major cause of epithelial
damage in TAK1 deleted mice. However, we found that, even in the absence of TNF
signaling, TAK1 deletion causes ileitis and colitis at P17–20. This suggests that TAK1 is
important not only for preventing TNF-induced tissue damage but also for intestinal
integrity that is regulated through a TNF independent mechanism. One possibility is
involvement of other TNF family receptor ligands such as TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) and FasL, which could also initiate an intracellular
apoptotic signaling pathway. TNF, TRAIL and FasL share the same apoptosis-signaling
pathway (32). Our preliminary results demonstrate that TAK1 deficiency in keratinocytes,
skin epithelial cells, increases sensitivity not only to TNF but also to TRAIL and FasL.
TRAIL and FasL may be responsible for inflammation in TAK1-deficient enterocytes.
Alternatively, this delayed inflammatory condition may be caused by increased
susceptibility to bacterial invasion due to reduced innate immune responses in TAK1
deficient enterocytes. TAK1 has been shown to be essential for production of cytokines/
chemokines, which prevent tissue damage, in response to TLRs and NOD2 activation (1,10).
Impairment of commensal bacteria-induced innate immunity in the intestine could enhance
intestinal epithelial damage (33). Therefore, it is likely that TAK1 deficient enterocytes do
not fully respond to commensal bacteria, and this may contribute to the development of
ileitis and colitis. We propose that TAK1 signaling is essential to maintain intestinal
homeostasis through induction of cytoprotective genes in enterocytes. Further studies will be
necessary to determine the molecular mechanism of TNF-dependent and independent
TAK1-mediated cytoprotective function in the intestine.
TAK1 is known to be involved in TGF-β and Wnt signaling pathways (34–37), and could
participate in the epithelial development and renewal. Although enterocyte’s differentiation
is largely normal in TAK1 deficient enterocytes, we cannot rule out the possibility that
TAK1 deletion partially impairs cell proliferation/differentiation and causes ileitis and
colitis at P17–20. Additionally, cytokine- and bacteria-mediated barrier function may be
impaired in enterocyte-derived TAK1 deficient mice causing a dysregulated translocation of
luminal antigens and development of ileitis and colitis. Regardless of the mechanism of
action, our findings identify enterocyte-derived TAK1 signaling as a critical component of
intestinal homeostasis and consequently as a potential therapeutic target for intestinal
inflammatory disorders.
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Figure 1. TAK1 is ubiquitously expressed and enterocytes-specific TAK1 deletion causes
intestinal damage
(a) Sections of the small intestine and colon from P0 control TAK1FL/FL mouse were
immunostained with control rabbit IgG (control), or anti-TAK1 (TAK1) along with anti-
Nidgen antibody and DAPI. Control rabbit IgG and TAK1 are red and Nidgen is green. Blue
indicates nuclei stained with DAPI. Scale bars, 50 µm.
(b) Control TAK1FL/FL (TAK1F/F) and villin-CreTAK1FL/FL (vil-CreTAK1F/F) mice at P0
(top panels). The intestine of control and villin-CreTAK1FL/FL mice at P0 and E18.5 (middle
and bottem panels).
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(c) The length of small intestine (left panel) and colon (right panel) of control TAK1FL/FL
(TAK1F/F, open bars) and villin-CreTAK1FL/FL (vil-CreTAK1F/F, filled bars) mice at P0.
Data show the means ± S.E. (TAK1FL/FL, n=46; villin-CreTAK1FL/FL, n=26). The results of
student t test (P) are shown above the graph.
(d) Histological scores from control (TAK1F/F) and villin-CreTAK1FL/FL (vil-CreTAK1F/F)
mice at P0 and E18.5. Data show the means ± S.E. and the P values (student t test) (n=5).
(e) Small intestinal and colonic sections from control (TAK1F/F) and villin-CreTAK1FL/FL
(vil-CreTAK1F/F) mice at P0 and E18.5 were stained with hematoxylin/eosin. Scale bars, 50
µm in low magnification, 20 µm in high magnification.
(f) The length of cripts-villi axes of control (TAK1F/F, open bars) and villin-CreTAK1 FL/FL
(vil-CreTAK1F/F, filled bars) mice at E18.5. Data show the means ± S.E. (TAK1FL/FL; n=18,
villin-CreTAK1FL/FL; n=10). NS, not significant
(g) Alcian Blue staining for identifying goblet cells in the small intestine and the colon from
control (TAK1F/F) and villin-CreTAK1FL/FL (vil-CreTAK1F/F) mice at P0 and E18.5. Goblet
cells were stained with blue. Arrows indicate smaller goblet cells. Scale bars, 50 µm (top
and middle panels), 25 µm (bottom panels). The percentages of goblet cells of the total
enterocytes in the small intestine at P0 (TAK1FL/FL, n=17; villin-CreTAK1FL/FL, n=16) and
E18.5 (TAK1FL/FL, n=20; villin-CreTAK1FL/FL, n=12) were shown. Data show the means ±
S.E. NS, not significant.
(h) Small intestinal sections from control TAK1FL/FL (TAK1F/F) and villin-CreTAK1FL/FL
(vil-CreTAK1F/F) mice at P0 and E18.5 were immunostained with anti-Synaptophysin (red).
Blue indicates nuclei stained with DAPI. Arrows indicate enteroendocrine cells. Scale bars,
50 µm. The number of enteroendocrine cells in the small intestine at P0 (TAK1FL/FL, n=12;
villin-CreTAK1FL/FL, n=7) and E18.5 (TAK1FL/FL, n=6; villin-CreTAK1FL/FL, n=5) were
shown. Data show the means ± S.E. NS, not significant.
(i) RNAs were isolated from the small intestine of control TAK1FL/FL (TAK1 F/F, open bars)
and villin-CreTAK1FL/FL (vil-CreTAK1F/F, filled bars) at E18.5. Real-time PCR analysis
was performed to quantify paneth cell marker: Mmp7 and enteroendocrine cell marker:
Ngn3 expression levels. Relative mRNA levels were calculated using GAPDH mRNAs.
Data show the means ± S.E. (TAK1FL/FL, n=11; villin-CreTAK1FL/FL, n=10). NS, not
significant.
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Figure 2. TAK1 deletion causes apoptosis and inflammation at E18.5-P0
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(a) TUNEL assay was performed on small intestinal and colonic sections of control
(TAK1 F/F) and villin-CreTAK1FL/FL (vil-CreTAK1F/F) mice at P0 and E18.5. Scale bars, 50
µm in low magnification, 20 µm in high magnification.
(b) Small intestinal and colonic sections from control TAK1FL/FL (TAK1F/F) and villin-
CreTAK1FL/FL (vil-CreTAK1F/F) mice at P0 and E18.5 were immunostained with anti-
Cleaved Caspase-3 antibody (red). Blue indicates nuclei stained with DAPI. Arrows indicate
examples of apoptotic cells. Scale bars, 20 mm.
(c) Quantification of mRNA levels in the control (TAK1F/F) and villin-CreTAK1FL/FL (vil-
CreTAK1F/F, filled bars) small intestine and colon at P0 by real-time PCR. mRNA levels
relative to GAPDH mRNA are shown. In P0 small intestine, data show the means ± S.E.
(TAK1FL/FL, n=27; villin-CreTAK1FL/FL, n=14; MIP-2, p < 0.009; S100A9, p < 0.02), and in
P0 colon, data show the means ± S.E. (TAK1FL/FL, n=11; villin-CreTAK1FL/FL, n=8; MIP-2,
p < 0.092; S100A9, p < 0.05).
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Figure 3. TAK1 is required for prevention of apoptosis and inflammation in 4-week-old mice
(a) Control (TAK1F/F) and villin-CreERT2TAK1FL/FL (vil-CreERT2TAK1F/F) 4-week-old
mice were injected with tamoxifen for 2 days. Immunoblot analysis of TAK1 in enterocytes.
β-actin was used as a loading control. Asterisk indicates non-specific band.
(b) Genomic PCR analysis for floxed TAK1 (TAK1Flox), villin-CreERT2 (vil-CreERT2) and
truncated TAK1 (TAK1Δ) in enterocytes (intestinal epithelial cell (IEC)), liver, kidney and
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heart of control TAK1FL/FL (CT) and villin-CreERT2TAK1FL/FL (MT) mice injected with
tamoxifen for 2 days.
(c) Real-time PCR analysis to quantify full-length TAK1 mRNA levels isolated from the
whole small intestine and colon. Relative mRNA levels were calculated using GAPDH
mRNAs. Data show the means ± S.E. (Small intestine, TAK1FL/FL, n=8; villin-CreERT2
TAK1FL/FL, n=9, Colon, TAK1FL/FL, n=8; villin-CreERT2 TAK1FL/FL, n=9).
(d) Small intestinal and colonic sections from 4-week-old mice of control (TAK1 F/F) and
villin-CreERT2TAK1FL/FL (vil-CreERT2TAK1F/F) treated with tamoxifen (Day 2 and Day 3)
were stained with hematoxylin/eosin. Scale bars, 50 µm.
(e) TUNEL staining of small intestinal and colonic sections from 4-week-old mice of control
TAK1FL/FL (TAK1 F/F) and villin-CreERT2TAK1FL/FL (vil-CreERT2TAK1F/F) treated with
tamoxifen (Day 2 and Day 3). Scale bars, 50 µm in low magnification, 20 µm in high
magnification.
(f) Small intestinal and colonic sections from 4-weeks-old mice of control TAK1FL/FL
(TNFR1F/F) and villin-CreERT2TAK1FL/FL (vil-CreERT2TAK1F/F) with tamoxifen treatment
for 2 days (Day 2) and for 3 days (Day 3) were stained with anti-Cleaved Caspase-3
antibody (red). Blue indicates nuclei stained with DAPI. Scale bars, 20 µm.
(g) (left panels) Productions of IL-1β and IL-6 in the small intestines from TAK1FL/FL
(TAK1F/F, open bars) and villin-CreTAK1FL/FL (vil-CreTAK1F/F, filled bars) mice injected
with tamoxifen for 3 days at 4-week-old. Data are representative of three independent
experiments. (right paneles) Real-time PCR analysis was performed in colon from control
(TAK1F/F, open bars) and villin-CreERT2TAK1FL/FL (vil-CreERT2TAK1F/F, filled bars)
mice treated with tamoxifen (Day 2). mRNA levels relative to GAPDH mRNA are shown.
Day 2, TAK1FL/FL, n=6; villin-CreERT2TAK1FL/FL; IL-1β, p < 0.15; IL-6, p < 0.066; MIP-2,
p < 0.022; S100A9, p < 0.017.
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Figure 4. The level of TNF is increased around the time of birth and further as mice grow
TNF mRNA levels in the small intestine at E16.5, E18.5 and P0 (left panel), and at P0, 2-
week-old and 4-week-old (right panel) were analyzed by real-time PCR. Because the levels
of TNF expression was unaffected by genotype, data from two genotypes, TAK1F/F and
TAK1F/+, (left panel) or from three genotypes, villin-CreERT2TAK1FL/FL, villin-
CreERT2TAK1+/+ and villin-CreERT2TAK1FL/+ without tamoxifen treatment, (right panel)
were combined. mRNA levels from relative to GAPDH mRNA are shown. (left panel,
E16.5, n=5; E18.5, n=22; P0, n=27) (right panel, ,P0, n=7; 2-week-old, n=7; 4-week-old,
n=7). The results of student t test (P) are shown above the graph.
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Figure 5. Tissue damage in TAK1 mutant mice is rescued by TNFR1 deletion
(a) TAK1 protein in enterocytes prepared from control TAK1FL/FL TNFR1−/− (TNFR1−/−)
and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice at P15 was analyzed by immunoblotting.
β-actin was used as a loading control. Asterisk indicates non-specific band.
(b) Real-time PCR analysis to quantify full-length TAK1 mRNA. RNAs were isolated from
control TAK1FL/FL TNFR1−/− (TNFR−/−) and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice
at 2–3 weeks old. mRNA levels relative to GAPDH mRNA are shown. Data show the means
± S.E. (TNFR1−/−, n=8; DKO, n=8).
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(c) Hematoxylin/eosin staining on sections of small intestine and colon from control
TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice at P0.
Scale bars, 50 µm in low magnification, 25 µm in high magnification.
(d) TUNEL assay was performed on small intestinal and colonic sections of control
TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice at P0.
Scale bars, 50 µm.
(e) Expression levels of the indicated genes in the control TAK1FL/FL TNFR1−/−
(TNFR1−/−, open bars) and villin-CreTAK1FL/FL TNFR1−/− (DKO, filled bars) small
intestine at P0. mRNA levels relative to GAPDH mRNA are shown. TNFR1−/−, n=13;
DKO, n=11; IL-1β, NS, p < 0.511; IL-6, NS, p < 0.655; MIP-2, NS, p < 0.466; S100A9, NS,
p < 0.603). NS, not significant.
(f) Alcian Blue staining for identifying goblet cells in the small intestine and the colon from
control TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL TNFR1−/− (DKO) P15
mice. Scale bars, 50 µm. The percentages of goblet cells in the small intestine at P0
(TAK1FL/FL TNFR1−/−, n=18; villin-CreTAK1FL/FL TNFR1−/−, n=18) were shown. Data
show the means ± S.E. NS, not significant.
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Figure 6. Older double-mutant mice with intestinal epithelium-specific TAK1 deletion and
TNFR1 deletion spontaneously develop ileitis and colitis
(a) Percentage of body weight relative to the body weight at P9 of control TAK1FL/FL
TNFR1−/− (TNFR1−/−, open circle) and villin-CreTAK1FL/FL TNFR1−/− (DKO, closed
circle) mice. The results show the means ± S.E. and the P value (student t test) at P17
(TNFR1−/−, n=19; DKO, n=10)
(b) (left panel) Colons from control and DKO at P16. (right panel) The colon length of
control TAK1FL/FLTNFR1−/− (TNFR1−/−, open bars) and villin-CreTAK1FL/FLTNFR1−/−
(DKO, filled bars) mice at P15–P18. Data show the means ± S.E. and the P value (student t
test) (TNFR1−/−, n=9; DKO, n=12).
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(c) Histological scores from control TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-
CreTAK1FL/FL TNFR1−/− (DKO) P15–P18 mice. Data show the means ± S.E. and the P
value (student t test) (n=4).
(d) Hematoxylin/eosin staining was performed on sections of the small intestine and the
colon from control TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL TNFR1−/−
(DKO) P15 mice. Scale bars, 50 µm.
(e) Sections of control TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL
TNFR1−/− (DKO) P15 mice small intestine and colon were subjected to TUNEL analysis.
Scale bars, 50 µm in low magnification, 20 µm in high magnification.
(f) Small intestinal and colonic sections from control TAK1FL/FLTNFR1−/− (TNFR1−/−) and
villin-CreTAK1FL/FLTNFR1−/− (DKO) mice at P18 were immunostained with anti-Cleaved
Caspase-3 antibody (red). Blue indicates nuclei stained with DAPI. Scale bars, 20 mm.
(g) Quantification of the indicated gene expression by real-time PCR in the colon harvested
from control TAK1FL/FL TNFR1−/− (TNFR1−/−, open bars) and villin-CreTAK1FL/FL
TNFR1−/− (DKO, filled bars) 4-week-old mice. mRNA levels relative to GAPDH mRNA
are shown. TNFR1−/−, n=8; DKO, n=8; IL-6, p < 0.036; MIP-2, p < 0.008; S100A9, p <
0.012.
(h) Alcian Blue staining in the small intestine and the colon from control TAK1FL/FL
TNFR1−/− (TNFR1−/−) and villin-CreTAK1FL/FL TNFR1−/− (DKO) mice at P15. Goblet
cells were stained with blue. Scale bars, 50 µm.
(i) Small intestinal sections from control TAK1FL/FL TNFR1−/− (TNFR1−/−) and villin-
CreTAK1FL/FL TNFR1−/− (DKO) P15 mice were immunostained with anti-Lysozyme (red).
The red staining in the bottom of crypts represents paneth cells. The red staining around
villus are non-specific staining. Scale bars, 50 µm.
(j) Small intestinal and colonic sections from control TAK1FL/FLTNFR1−/− (TNFR1−/−) and
villin-CreTAK1FL/FLTNFR1−/− (DKO) mice at P18 were immunostained with anti-Ki67
antibody. Scale bars, 20 µm.
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Table 1
Correlation between apoptosis and the levels of inflammatory molecules at E18.5a



















TAK1FL/FL − 7   0.18 0.57 0.1 0.08 0.05 0.08 11.14 3.20
−   0.37 0.1 0.09 10.32
−   0.59 0.04 0.03 0.18
−   1.23 0.07 0.17 0.11
−   0.62 0.08 0.03 0.22
−   0.25 0.01 0.01 0.18
−   0.77 0.14 0.15 0.25
villin-Cre − 2   0.08 0.20 0.03 0.07 0.02 0.03 1.63 0.90
TAK1FL/FL −   0.31 0.1 0.03 0.17
+ 2   3.11 1.64 0.07 0.06 0.24 0.15 0.28 0.27
+   0.17 0.05 0.05 0.25
++ 3 14.5 37.09 2.56 4.63 14.70 20.28 25.59 99.94
++ 31.08 5.81 17.36 113.59
+++ 65.70 5.53 28.79 160.64
a
More than 6 small intestinal sections with TUNEL staining from each control (TAK1F/F) or villin-CreTAK1FL/FL (vil-CreTAK1F/F) mouse at
E18.5 were scored using the scale of −, +, ++ and +++ (−, no TUNEL positive cell was found; +, TUNEL positive cells were found in scattered
area of one or two sections; ++, TUNEL positive cells were found in a large area of more than 70% of sections; +++, TUNEL positive cells were
found in a large area of all sections). The RNA samples isolated from the same small intestines were subjected to quantification of mRNA levels.
mRNA levels relative to GAPDH mRNA are shown.
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